Jade Biosciences Inc (NASDAQ: JBIO) saw its shares slip 6.5% in after-hours trading Wednesday after the company unveiled plans for an underwritten public offering of its common stock.
The clinical-stage biotechnology company said it intends to offer and sell shares of its common stock or, alternatively, pre-funded warrants to purchase shares of its common stock to certain investors. In the filing, Jade made clear that all securities in the proposed offering would be sold by the company itself.
Under the proposed transaction, Jade will grant the underwriters a 30-day option to buy up to an additional 15% of the securities offered at the public offering price, less underwriting discounts and commissions. The company emphasized that there is no assurance regarding whether or when the proposed offering may be completed, or the eventual size or terms of any sale.
Jade outlined the intended use of net proceeds from the proposed offering. Together with its existing cash, cash equivalents and investments, the company said it would apply the funds to support clinical trials, preclinical studies and manufacturing activities tied to its programs. The company also indicated the proceeds would be available for additional research and development, capital expenditures, working capital and other general corporate purposes.
Several banks will coordinate the proposed offering. Jefferies, TD Cowen and UBS Investment Bank are listed as joint book-running managers. LifeSci Capital is also serving as a book-running manager, while BTIG is acting as lead manager.
Jade Biosciences focuses on developing therapies for autoimmune diseases. The company provided the offering framework and the intended allocation of proceeds but did not specify timing, pricing, or the final size of the transaction in its announcement.
Context and market reaction
Investors responded to the financing announcement in after-hours trading, with the stock recording a notable decline as the market digested the potential dilution implicit in an equity offering. Jade’s statement makes clear the offering remains subject to market and other customary conditions and may not be completed.
The company’s description of purposes for the proceeds reflects typical funding needs for a clinical-stage biotech, including support for trials, manufacturing and ongoing R&D programs.